ROBERT LAITMAN: Open Payments
NPI 1427046689 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 45 payments from 7 companies in 2025. Trend: 2023 $355 · 2024 $356 · 2025 $1,209
Food & beverage: $1,209
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $507 |
| E.R. Squibb & Sons, L.L.C. | 16 | $399 |
| Teva Pharmaceuticals USA, Inc. | 7 | $185 |
| Lilly USA, LLC | 2 | $52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: INGREZZA, COBENFY, AUSTEDO XR, MOUNJARO, JARDIANCE, REXULTI.
Industry payments across NY — which companies pay providers there.
